Thai PBS Thai PBS
WHO backs antibody treatment for high-risk Covid patients

WHO backs antibody treatment for high-risk Covid patients

21 Sept 04:45 Key points summarised by AI
  • The World Health Organization (WHO) officially recommended Regeneron's synthetic antibody treatment (casirivimab and imdevimab) for Covid-19 patients, marking it as only the third treatment endorsed by the global health authority.
  • The treatment is specifically recommended for two groups: individuals with non-severe Covid-19 who are at high risk of hospitalization, and critically ill patients unable to mount an adequate immune response.
  • The Regeneron cocktail has shown promise in reducing hospitalization risk for unvaccinated, elderly, or immunosuppressed patients, and decreasing deaths/ventilation needs in critically ill patients.
  • Despite welcoming the new therapeutic, WHO expressed significant concern over the high cost and limited availability of the treatment, urging negotiations for lower prices and equitable global distribution, especially in low- and middle-income countries.
Read full article
World 1/2
Skip > Skip >